The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of gemcitabine and S-1 therapy in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP-03).
Akio Saiura
No relevant relationships to disclose
Hideki Ueno
Honoraria - Lilly; Taiho Pharmaceutical
Tomoo Kosuge
No relevant relationships to disclose
Yutaka Matsuyama
No relevant relationships to disclose
Hiroshi Ishii
No relevant relationships to disclose
Akimasa Nakao
No relevant relationships to disclose
Ryuichiro Doi
No relevant relationships to disclose
Masao Tanaka
Consultant or Advisory Role - Taiho Pharmaceutical
Honoraria - Taiho Pharmaceutical